The Phase 1 data strongly de-risk CLYM116's best-in-class potential in IgAN with a compelling Q12W profile. Traders should watch for additional Phase 1 data at a medical meeting in Q4 2026 and initial Phase 2 data in H1 2027 as key catalysts. The stock is likely to re-rate on the strength of these data, but the binary risk of Phase 2 failure remains.
Price Chart
Executive Summary
Climb Bio announced positive initial Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy (IgAN). The data showed a ~29-day half-life (3x longer than sibeprenlimab), >90% free APRIL suppression, and ~60-75% IgA/Gd-IgA1 suppression through 12 weeks with a single 320 mg dose, supporting a potential every-12-week (Q12W) dosing regimen. The Phase 2 NAVIGATE-2 trial is ongoing with initial data expected in H1 2027, and Phase 3 initiation anticipated in 2027.
Key Facts
- CLYM116 demonstrated a ~29-day half-life, threefold longer than sibeprenlimab.
- A single 320 mg dose achieved >90% free APRIL suppression and ~60-75% suppression of IgA, Gd-IgA1, and IgM through 12 weeks.
- No serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia were observed.
- Target dosing regimen defined as 800 mg loading dose followed by 400 mg Q12W, supported by PK/PD modeling.
- Phase 2 NAVIGATE-2 trial in IgAN is enrolling; initial data anticipated in H1 2027.
- Phase 3 registrational study initiation anticipated in 2027.
- High concentration (200 mg/mL) formulation and pre-filled syringe development are complete.
Financial Impact
No financial data reported. The company is a clinical-stage biotech with no approved products or revenue.
Risk Factors
- Phase 2 NAVIGATE-2 data may not replicate Phase 1 healthy volunteer results in IgAN patients.
- Competitive landscape includes approved and late-stage APRIL/BAFF inhibitors (sibeprenlimab, atacicept, povetacicept).
- The company will need substantial additional capital to fund Phase 3 development.
- Cross-trial comparisons with competitors are limited and may not reflect head-to-head performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-381060 |
| Document: d97033d8k.htm | 0001193125-26-381060 |
| Document: d97033dex991.htm | 0001193125-26-381060 |
| Document: 0001193125-26-381060-index-headers.html | 0001193125-26-381060 |
| Document: 0001193125-26-381060-index.html | 0001193125-26-381060 |
| Document: 0001193125-26-381060.txt | 0001193125-26-381060 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+1 | — | — |
Oct 23, 2026 3d ago | 8-K | $10.47 | awaiting T+1 | — | $8.81 (−15.85%) |
Oct 23, 2026 3d ago | Press Release | $10.34 | awaiting T+1 | — | $8.81 (−14.80%) |
Sep 22, 2026 4w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $8.81 (−38.00%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $8.81 (−39.62%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $8.81 (−46.05%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $8.81 (−37.07%) |
Jun 30, 2026 16w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $8.81 (−33.71%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $8.81 (+23.32%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $8.81 (+23.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers